Vertex gets in on GPCR game, paying Septerna $47M for undisclosed program

Only two months after snagging $150 million from investors to take its first G-protein-coupled receptor (GPCR) drug into the clinic, Septerna has added another $47.5 million to the pile courtesy of a licensing deal with Vertex.